Teysuno 15 mg/4.35 mg/11.8 mg hard capsules

DRUG4 trials

Sponsors

Amsterdam UMC, Catharina Ziekenhuis Stichting, HUS-Yhtymae, Het Nederlands Kanker Instituut-Antoni van Leeuwenhoek Ziekenhuis Stichting

Conditions

Breast cancerColon cancerLocally recurrent rectal cancerTriple negative breast cancermetastatic pancreatic cancer

Phase 2

A randomized phase II study of second line treatment with liposomal irinotecan and S1 versus liposomal irinotecan and 5-fluorouracil in patients with metastatic pancreatic cancer who failed on first line gemcitabine-based chemotherapy

Active, not recruitingCTIS2023-509463-24-01

Amsterdam UMCmetastatic pancreatic cancer

Start: 2019-11-04Target: 146Updated: 2025-01-09

Phase 3

Multicentre, open-label, randomized, controlled, parallel arms clinical trial of induction chemotherapy followed by chemoradiotherapy versus chemoradiotherapy alone as neoadjuvant treatment for locally recurrent rectal cancer (PelvEx II)

RecruitingCTIS2024-512526-28-00

Catharina Ziekenhuis StichtingLocally recurrent rectal cancer

Start: 2020-10-28Target: 364Updated: 2026-01-19

DPDIMP#1-trial: Impact of DPYD gene test on the safety and efficacy of fluoropyrimidine therapy

CompletedCTIS2024-518448-20-00

HUS-YhtymaeBreast cancer, Colon cancer

Start: 2019-10-17End: 2025-03-17Target: 1000Updated: 2024-10-29

PembroLizumab Adjuvant in patients with early-stage Triple NEgaTive breast cancer with residual disease after neoadjuvant pembrolizumab plus chemotherapy – the multicenter, randomized phase III, pragmatic PLANET trial

Not yet recruitingCTIS2025-524229-41-00

Het Nederlands Kanker Instituut-Antoni van Leeuwenhoek Ziekenhuis StichtingTriple negative breast cancer

Target: 1000Updated: 2026-04-01